Salix Pharmaceuticals has signed new agreements to market its Colazal intestinal drug in Australia, New Zealand and Puerto Rico.
Pharmatel PTY of Sydney will sell Colazal in Australia and New Zealand.
Salix will work with Rimaco for distribution in Puerto Rico.
Pharmatel also made a one-time milestone payment to Salix for the rights to fund a study of using Colazal to treat irritable bowel syndrome. Salix said it retains first right of negotiation for all Pharmatel gastrointestinal products.